作者
Simone JCFM Moorlag, Esther Taks, Thijs Ten Doesschate, Thomas W van der Vaart, Axel B Janssen, Lisa Müller, Philipp Ostermann, Helga Dijkstra, Heidi Lemmers, Elles Simonetti, Marc Mazur, Heiner Schaal, Rob Ter Heine, Frank L van de Veerdonk, Chantal P Bleeker-Rovers, Reinout van Crevel, Jaap Ten Oever, Marien I de Jonge, Marc J Bonten, Cornelis H van Werkhoven, Mihai G Netea
发表日期
2022/7/1
期刊
Clinical Infectious Diseases
卷号
75
期号
1
页码范围
e938-e946
出版商
Oxford University Press
简介
Background
Older age is associated with increased severity and death from respiratory infections, including coronavirus disease 2019 (COVID-19). The tuberculosis BCG vaccine may provide heterologous protection against nontuberculous infections and has been proposed as a potential preventive strategy against COVID-19.
Methods
In this multicenter, placebo-controlled trial, we randomly assigned older adults (aged ≥60 years; n = 2014) to intracutaneous vaccination with BCG vaccine (n = 1008) or placebo (n = 1006). The primary end point was the cumulative incidence of respiratory tract infections (RTIs) that required medical intervention, during 12 months of follow-up. Secondary end points included the incidence of COVID-19, and the effect of BCG vaccination on the cellular and humoral immune responses.
Results
The cumulative incidence …
学术搜索中的文章
SJ Moorlag, E Taks, T Ten Doesschate… - Clinical Infectious Diseases, 2022